Contact Us
Drug Search Results
More Filters [+]

CBX-129801

Alternative Names: cbx-129801, cbx129801, cbx 129801
Latest Update: 2023-01-01
Latest Update Note: PubMed Publication

Product Description

A pegylated form of human synthetic C-peptide (CBX129801) has been developed to extend the half-life of the native peptide and is undergoing clinical investigation as replacement therapy to treat diabetic peripheral neuropathy.

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Cebix
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CBX-129801

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Type 1 Diabetes|Peripheral Nervous System Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2012-001246-17

P2

Completed

Type 1 Diabetes

2014-12-02

CBX129801-DN-201

P2

Completed

Type 1 Diabetes|Peripheral Nervous System Diseases

2014-11-01

CBX129801-PK-101

P2

Completed

Type 1 Diabetes

2012-08-01

Recent News Events

Date

Type

Title

01/01/2023

PubMed

 Time-dependent association between omeprazole and esomeprazole and hospitalization due to hyponatremia.

09/01/2021

PubMed

 Non-thiazide diuretics and hospitalization due to hyponatraemia: A population-based case-control study.

07/01/2021

PubMed

 Association between newly initiated thiazide diuretics and hospitalization due to hyponatremia.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions